ST3 beta-galactoside alpha-2,3-sialyltransferase 1 (ST3Gal1) synthesis of Siglec ligands mediates anti-tumour immunity in prostate cancer. (2024)

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1038/s42003-024-05924-0

PubMed Identifier: 38448753

Publication URI: http://europepmc.org/abstract/MED/38448753

Type: Journal Article/Review

Volume: 7

Parent Publication: Communications biology

Issue: 1

ISSN: 2399-3642